Mark K Doherty1, Vincent C Tam2, Mairéad G McNamara3, Raymond Jang1, David Hedley1, Eric Chen1, Neesha Dhani1, Patricia Tang2, Hao-Wen Sim1, Grainne M O'Kane1, Stephanie DeLuca4, Lisa Wang5, Theresa Pedutem6, Jennifer J Knox7. 1. Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. 2. Department of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada. 3. Division of Cancer Sciences, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK. 4. Pharmacy, Princess Margaret Cancer Centre, Toronto, ON, Canada. 5. Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada. 6. Drug Development Program, Princess Margaret Cancer Centre, Toronto, ON, Canada. 7. Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. Jennifer.knox@uhn.ca.
Abstract
INTRODUCTION: Cisplatin and gemcitabine (CisGem) are standard chemotherapy for advanced biliary tract cancer (BTC). The MEK inhibitor selumetinib showed synergy with gemcitabine when administered sequentially in BTC. This randomised Phase 2 trial aimed to assess the efficacy of sequential or continuous selumetinib with CisGem. METHODS: Patients with advanced BTC received CisGem; arm A included selumetinib every day, arm B: selumetinib, days 1-5, 8-19 each cycle. Arm C received CisGem alone. Selumetinib was dosed at 75 mg BID but amended to 50 mg BID due to toxicity. RESULTS: In all, 51 participants were evaluable for response. No significant difference was seen in mean change in tumour size at 10 weeks between arms A and C (-7.8% vs -12.8%, P = 0.54) or arms B and C (-15% vs -12.8%, P = 0.78). There was no difference in median progression-free survival (6.0, 7.0, 6.3 months, P > 0.95) or overall survival (11.7, 11.7, 12.8 months, P = 0.70) for arms A, B and C, respectively. More participants experienced grade 3-4 toxicities in selumetinib-containing arms. More participants in arm A required chemotherapy dose reductions (P = 0.01) with lower chemotherapy dose intensity during the first 10 weeks. CONCLUSION: Adding sequential or continuous selumetinib to CisGem failed to improve efficacy and increased toxicity in patients with advanced BTC.
INTRODUCTION: Cisplatin and gemcitabine (CisGem) are standard chemotherapy for advanced biliary tract cancer (BTC). The MEK inhibitor selumetinib showed synergy with gemcitabine when administered sequentially in BTC. This randomised Phase 2 trial aimed to assess the efficacy of sequential or continuous selumetinib with CisGem. METHODS: Patients with advanced BTC received CisGem; arm A included selumetinib every day, arm B: selumetinib, days 1-5, 8-19 each cycle. Arm C received CisGem alone. Selumetinib was dosed at 75 mg BID but amended to 50 mg BID due to toxicity. RESULTS: In all, 51 participants were evaluable for response. No significant difference was seen in mean change in tumour size at 10 weeks between arms A and C (-7.8% vs -12.8%, P = 0.54) or arms B and C (-15% vs -12.8%, P = 0.78). There was no difference in median progression-free survival (6.0, 7.0, 6.3 months, P > 0.95) or overall survival (11.7, 11.7, 12.8 months, P = 0.70) for arms A, B and C, respectively. More participants experienced grade 3-4 toxicities in selumetinib-containing arms. More participants in arm A required chemotherapy dose reductions (P = 0.01) with lower chemotherapy dose intensity during the first 10 weeks. CONCLUSION: Adding sequential or continuous selumetinib to CisGem failed to improve efficacy and increased toxicity in patients with advanced BTC.
Authors: Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater Journal: N Engl J Med Date: 2010-04-08 Impact factor: 91.245
Authors: Junyao Xu; Jennifer J Knox; Emin Ibrahimov; Eric Chen; Stefano Serra; Ming Tsao; Pinjiang Cao; Douglass Vines; David E Green; Cristiane Metran-Nascente; Mairead G McNamara; David W Hedley Journal: Clin Cancer Res Date: 2012-10-22 Impact factor: 12.531
Authors: A Demols; I Borbath; M Van den Eynde; G Houbiers; M Peeters; R Marechal; T Delaunoit; J-C Goemine; S Laurent; S Holbrechts; M Paesmans; J-L Van Laethem Journal: Ann Oncol Date: 2020-05-25 Impact factor: 32.976
Authors: Ghassan K Abou-Alfa; Vaibhav Sahai; Antoine Hollebecque; Gina Vaccaro; Davide Melisi; Raed Al-Rajabi; Andrew S Paulson; Mitesh J Borad; David Gallinson; Adrian G Murphy; Do-Youn Oh; Efrat Dotan; Daniel V Catenacci; Eric Van Cutsem; Tao Ji; Christine F Lihou; Huiling Zhen; Luis Féliz; Arndt Vogel Journal: Lancet Oncol Date: 2020-03-20 Impact factor: 41.316
Authors: Vivek Subbiah; Ulrik Lassen; Elena Élez; Antoine Italiano; Giuseppe Curigliano; Milind Javle; Filippo de Braud; Gerald W Prager; Richard Greil; Alexander Stein; Angelica Fasolo; Jan H M Schellens; Patrick Y Wen; Kert Viele; Aislyn D Boran; Eduard Gasal; Paul Burgess; Palanichamy Ilankumaran; Zev A Wainberg Journal: Lancet Oncol Date: 2020-08-17 Impact factor: 41.316
Authors: Ghassan K Abou-Alfa; Teresa Macarulla; Milind M Javle; Robin K Kelley; Sam J Lubner; Jorge Adeva; James M Cleary; Daniel V Catenacci; Mitesh J Borad; John Bridgewater; William P Harris; Adrian G Murphy; Do-Youn Oh; Jonathan Whisenant; Maeve A Lowery; Lipika Goyal; Rachna T Shroff; Anthony B El-Khoueiry; Bin Fan; Bin Wu; Christina X Chamberlain; Liewen Jiang; Camelia Gliser; Shuchi S Pandya; Juan W Valle; Andrew X Zhu Journal: Lancet Oncol Date: 2020-05-13 Impact factor: 41.316
Authors: John Bridgewater; Andre Lopes; Sandra Beare; Marian Duggan; Dymphna Lee; Maravic Ricamara; Delyth McEntee; Ajithkumar Sukumaran; Harpreet Wasan; Juan W Valle Journal: BMC Cancer Date: 2016-02-24 Impact factor: 4.430
Authors: Juan W Valle; Harpreet Wasan; Andre Lopes; Alison C Backen; Daniel H Palmer; Karen Morris; Marian Duggan; David Cunningham; D Alan Anthoney; Pippa Corrie; Srinivasan Madhusudan; Anthony Maraveyas; Paul J Ross; Justin S Waters; Will P Steward; Charlotte Rees; Sandy Beare; Caroline Dive; John A Bridgewater Journal: Lancet Oncol Date: 2015-07-12 Impact factor: 41.316
Authors: Alastair Greystoke; Nicola Steele; Hendrik-Tobias Arkenau; Fiona Blackhall; Noor Md Haris; Colin R Lindsay; Raffaele Califano; Mark Voskoboynik; Yvonne Summers; Karen So; Dana Ghiorghiu; Angela W Dymond; Stuart Hossack; Ruth Plummer; Emma Dean Journal: Br J Cancer Date: 2017-08-24 Impact factor: 7.640